Valeris Targets Medical Benefit Maximizers with Proprietary Tech
Event summary
- Valeris has begun disrupting medical benefit maximizer activity, an emerging trend largely unaddressed by competitors.
- The company's proprietary Policy Reporter™ technology identifies plan administrators and targeted drugs under medical benefit maximizer health plans.
- Valeris has identified 200 brands affected by these tactics and is taking proactive measures to counter them.
- Michael Harris, VP of Patient Support Services Strategy at Valeris, highlights 2026 as a year of innovation for the company in this space.
The big picture
Valeris is addressing a strategic gap in the market by tackling medical benefit maximizers, an area largely overlooked by other patient affordability providers. This move positions Valeris as a leader in identifying and countering emerging payer tactics, potentially reshaping how life sciences companies safeguard their brands and patients. The company's proprietary technology gives it a distinct advantage in a rapidly evolving healthcare commercialization landscape.
What we're watching
- Technology Scalability
- How Valeris will scale its proprietary technology to address the growing number of affected brands and patients.
- Competitive Response
- Whether competitors will develop similar capabilities or if Valeris can maintain a first-mover advantage.
- Regulatory Impact
- The pace at which regulatory bodies may address medical benefit maximizer tactics and their potential influence on Valeris' strategy.